Similar articles

Abstract: Objective: In postmenopausal women, an increased leptin concentration and reduced levels of ghrelin and adiponectin were observed. The aim of this study was to evaluate the concentrations of the active form of ghrelin, total ghrelin, leptin receptor, lipoprotein(a) (Lp(a)), and plasminogen activator inhibitor type 1 (PAI-1) in postmenopausal women who received oral or transdermal menopausal hormonal therapy (MHT). Methods: The study involved 76 healthy women: 46 women aged from 44 to 58 years who received oral (26) or transdermal (20) MHT; the control group consisted of 30 women aged from 44 to 54 years who did not receive MHT. The plasma concentrations of total ghrelin, the active form of ghrelin, Lp(a), and PAI-1:Ag were measured by enzyme-linked immunosorbent assay (ELISA). The concentration of the leptin receptor was measured by enzyme immunometric assay (EIA). Results: We observed a significantly higher concentration of total ghrelin and the active form of ghrelin in women who received transdermal MHT in comparison with those who took oral MHT. We also found a significantly lower concentration of total ghrelin in women who received oral MHT compared with the control group. A higher concentration of PAI-1:Ag was found in the group of women who took transdermal MHT in comparison with those who took oral MHT and with the control group. The differences were statistically significant. Additionally, we found a significant negative correlation between the concentrations of total ghrelin and PAI-1:Ag and a positive correlation between the concentrations of total ghrelin and leptin receptor in women who received transdermal MHT. Conclusions: The study showed that women who used transdermal MHT had higher levels of total ghrelin than women who took oral MHT. This indicates a beneficial effect of the transdermal route of MHT. However, transdermal therapy was associated with adverse effects with regard to the observed higher levels of PAI-1:Ag, which in turn, can lead to a reduction in fibrinolytic activity.

[1]Bagnasco, M., Kalra, P.S., Kalra, S.P., 2002. Ghrelin and leptin pulse discharge in fed and fasted rats. Endocrinology, 143(2):726-729.

[2]Cagnacci, A., Malmusi, S., Arangino, S., 2002. Influence of transdermal estradiol in the regulation of leptin levels of postmenopausal women: a double-blind, placebo-controlled study. Menopause, 9(1):65-71.

[3]Christian Schulze, P., Kratzsch, J., Linke, A., Schoene, N., Adams, V., Gielen, S., Erbs, S., Moebius-Winkler, S., Schuler, G., 2003. Elevated serum levels of leptin and soluble leptin receptor in patients with advanced chronic heart failure. Eur. J. Heart Fail., 5(1):33-40.

[4]Cummings, D.E., Foster, K.E., 2003. Ghrelin-leptin tango in body-weight regulation. Gastroenterology, 124(5):1532-1535.

[5]di Carlo, C., Tommaselli, G.A., Gargano, V., Sammartino, A., Bifulco, G., Tauchmanova, L., Colao, A., Nappi, C., 2007. Effects of estrogen-progestin therapy on serum levels of RANKL, osteoprotegerin, osteocalcin, leptin, and ghrelin in postmenopausal women. Menopause, 14(1):38-44.

[6]Dobrovolsky, A.B., Titaeva, E.V., 2002. The fibrinolysis system: regulation of activity and physiologic functions of its main components. Biochemistry (Moscow), 67(1):99-108.

[7]Elbers, J.M., de Valk-de Roo, G.W., Popp-Snijders, C., Nicolaas-Merkus, A., Westerveen, E., Joenje, B.W., Netelenbos, J.C., 1999. Effects of administration of 17β-oestradiol on serum leptin levels in healthy postmenopausal women. Clin. Endocrinol., 51(4):449-454.

[8]Grinspoon, S., Miller, K.K., Herzog, D.B., Grieco, K.A., Klibanski, A., 2004. Effects of estrogen and recombinant human insulin-like growth factor-I on ghrelin secretion in severe under nutrition. J. Clin. Endocrinol. Metab., 89(8):3988-3993.

[9]Hoda, M.R., Keely, S.J., Bertelsen, L.S., 2007. Leptin acts as a mitogenic and antiapoptotic factor for colonic cancer cells. Br. J. Surg., 94(3):346-354.

[10]Isomoto, H., Ueno, H., Nishi, Y., Yasutake, T., Tanaka, K., Kawano, N., Ohnita, K., Mizuta, Y., Inoue, K., Nakazato, M., et al., 2005. Circulating ghrelin levels in patients with various upper gastrointestinal diseases. Dig. Dis. Sci., 50(5):833-838.

[11]Kellokoski, E., Pöykkö, S.M., Karjalainen, A.H., 2005. Estrogen replacement therapy increases plasma ghrelin levels. J. Clin. Endocrinol. Metabol., 90(5):2954-2963.

[12]Konturek, P.C., Brzozowski, T., Pajdo, R., 2004. Ghrelin a new gastroprotective factor in gastric mucosa. J. Physiol. Pharmacol., 55(2):325-336.

[13]Konukoglu, D., Serin, O., Ercan, M., 2000. Plasma leptin levels in obese and non-obese postmenopausal women before and after hormone replacement therapy. Maturitas, 36(3):203-207.

[14]Lambrinoudaki, I.V., Christodoulakos, G.E., Panoulis, C.P., Rizos, D.A., Dendrinos, S.G., Liakakos, T., Augoulea, A.D., Creatsas, G.C., 2004. Effect of hormone replacement therapy and tibolone on serum leptin levels in postmenopausal women. Maturitas, 48(2):107-113.

[15]Lambrinoudaki, I.V., Christodoulakos, G.E., Economou, E.V., Vlachou, S.A., Panoulis, C.P., Alexandrou, A.P., Kouskouni, E.E., Creatsas, G.C., 2008. Circulating leptin and ghrelin are differentially influenced by estrogen/ progestin therapy and raloxifene. Maturitas, 59(1):62-71.

[16]Meier, U., Gressner, A.M., 2004. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin. Chem., 50(9):1511-1525.

[17]Menon, D.V., Vongpatanasin, W., 2006. Effects of transdermal estrogen replacement therapy on cardiovascular risk factors. Treat. Endocrinol., 5(1):37-51.

[18]Michalski, B., Pakuła-Krzemińska, M., Kasprzak, J.G., 2008. The way to the heart is through the stomach—the role of ghrelin in pathogenesis of cardiovascular disease. Kardiol. Pol., 66(5):564-568 (in Polish).

[19]Mueck, A.O., Seeger, H., 2005. Smoking, estradiol metabolism and hormone replacement therapy. Curr. Med. Chem. Cardiovasc. Hematol. Agents, 3(1):45-54.

[20]Nishi, Y., Isomoto, H., Ueno, H., Ohnita, K., Wen, C.Y., Takeshima, F., Mishima, R., Nakazato, M., Kohno, S., 2005. Plasma leptin and ghrelin concentrations in patients with Crohn’s disease. World J. Gastroenterol., 11(46):7314-7317.

[21]Pertyński, T., Stachowiak, G., 2006. Choosing the route of drug administration for hormone therapy of the menopausal period—when is it worth to tuck for patches? Przegl. Menopauz., 5:323-328 (inPolish).

[22]Post, M.S., van der Mooren, M.J., van Baal, W.M., Blankenstein, M.A., Merkus, H.M., Kroeks, M.V., Franke, H.R., Kenemans, P., Stehouwer, C.D., 2003. Effects of low-dose oral and transdermal estrogen replacement therapy on hemostatic factors in healthy postmenopausal women: a randomized placebo-controlled study. Am. J. Obstet. Gynecol., 189(5):1221-1227.

[23]Ruszkowska, B., Manysiak, S., Małecka, B., Dymek, G., Rość, D., Odrowąż-Sypniewska, G., 2010a. Parameters of fibrinolysis in postmenopausal women taking oral or transdermal hormone replacement therapy. Adv. Clin. Exp. Med., 19(2):203-210.

[24]Ruszkowska, B., Manysiak, S., Bielis, L., Małecka, B., Dymek, G., Senterkiewicz, L., Rość, D., Odrowąż-Sypniewska, G., 2010b. TAFI (thrombin activatable fibrinolysis inhibitor) and parameters of its activation in postmenopausal women taking oral and transdermal hormone replacement therapy. Med. Biol. Sci., 24(3):43-49.

[25]Ruszkowska, B., Gadomska, G., Bielis, L., Gruszka, M., Góralczyk, B., Rość, D., Odrowąż-Sypniewska, G., 2011. Risk of venous thromboembolic disease in postmenopausal women taking oral or transdermal hormone replacement therapy. J. Zhejiang Univ.-Sci. B (Biomed. & Biotechnol.), 12(1):12-17.

[26]Shiiya, T., Nakazato, M., Mizuta, M., Date, Y., Mondal, M.S., Tanaka, M., Nozoe, S.I., Hosoda, H., Kangawa, K., Matsukura, S., 2002. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J. Clin. Endocrinol. Metab., 87(1):240-244.

[27]Stachowiak, G., Stetkiewicz, T., Połać, I., Sobczuk, A., Jędrzejczyk, S., Pertyński, T., 2005. The role of plasminogen activator inhibitor 1 (PAI-1) after menopause—the influence hormonal therapy of his period. Przegl. Menopauz., 6:17-21 (in Polish).

[28]Stachowiak, G., Zając, A., Pertyński, T., 2009. Metabolic syndrome in women in the menopausal period. Przegl. Menopauz., 1:6-10 (in Polish).

[29]Szumiło, M., Rahden-Staroń, I., Dubielecka, E., 2007. Adipose tissue-endocrine function in physiology and pathology. Farm. Pol., 23:1051-1065 (in Polish).

[30]Toshinai, K., Mondal, M.S., Nakazato, M., Date, Y., Murakami, N., Kojima, M., Kangawa, K., Matsukura, S., 2001. Upregulation of ghrelin expression in the stomach upon fasting, insulin-induced hypoglycemia, and leptin administration. Biochem. Biophys. Res. Commun., 281(5):1220-1225.

[31]Tschöp, M., Weyer, C., Tataranni, P.A., Devanarayan, V., Ravussin, E., Heiman, M.L., 2001. Circulating ghrelin levels are decreased in human obesity. Diabetes, 50(4):707-709.

[32]Weigle, D.S., Cummings, D.E., Newby, P.D., Breen, P.A., Frayo, R.S., Matthys, C.C., Callahan, H.S., Purnell, J.Q., 2003. Roles of leptin and ghrelin in the loss of body weight caused by a low fat, high carbohydrate diet. J. Clin. Endocrinol. Metab., 88(4):1577-1586.